Cargando…

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection

BACKGROUND: Estimated albumin excretion rate (eAER) provides a better estimate of 24-h albuminuria than albumin:creatinine ratio (ACR). However, whether eAER is superior to ACR in predicting end-stage renal disease (ESRD), vascular events (VEs) or death is uncertain. METHODS: The prognostic utility...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mafham, Marion M, Staplin, Natalie, Emberson, Jonathan, Haynes, Richard, Herrington, William, Reith, Christina, Wanner, Christoph, Walker, Robert, Cass, Alan, Levin, Adeera, Fellström, Bengt, Jiang, Lixin, Holdaas, Hallvard, Kasiske, Bertram, Wheeler, David C, Landray, Martin J, Baigent, Colin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837220/ https://www.ncbi.nlm.nih.gov/pubmed/28088776 http://dx.doi.org/10.1093/ndt/gfw396

Ejemplares similares

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
por: Reith, C., et al.
Publicado: (2017)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease
por: Herrington, William, et al.
Publicado: (2017)

Impact of CKD on Household Income
por: Morton, Rachael L., et al.
Publicado: (2017)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis
por: Mafham, Marion, et al.
Publicado: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
por: Baigent, Colin, et al.
Publicado: (2011)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
por: Staplin, Natalie, et al.
Publicado: (2021)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, Richard, et al.
Publicado: (2018)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial
por: Harper, Charlie, et al.
Publicado: (2021)

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
por: Harper, Charlie, et al.
Publicado: (2023)

Allocated but not treated: the silent 16% – Authors' reply
por: Horby, Peter, et al.
Publicado: (2022)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, Benjamin C., et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study
por: Fellström, Bengt, et al.
Publicado: (2005)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology
por: Staplin, Natalie, et al.
Publicado: (2022)

Albumin Urinary Excretion Is Associated with Increased Levels of Urinary Chemokines, Cytokines, and Growth Factors Levels in Humans
por: Fellström, Bengt, et al.
Publicado: (2021)

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
por: Baigent, Colin, et al.
Publicado: (2017)

What is the association of COVID-19 with heart attacks and strokes?
por: Mafham, Marion, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients
por: Pihlstrøm, Hege, et al.
Publicado: (2014)

Symmetric Dimethylarginine as Predictor of Graft loss and All-Cause Mortality in Renal Transplant Recipients
por: Pihlstrøm, Hege, et al.
Publicado: (2014)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial
por: Girerd, Sophie, et al.
Publicado: (2019)

Changes in Albumin Excretion in the Diabetes Prevention Program
Publicado: (2009)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Urinary Albumin Excretion and Vascular Function in Rheumatoid Arthritis
por: Pieringer, Herwig, et al.
Publicado: (2016)

Significance of urinary albumin excretion in patients with cast nephropathy
por: Nakagawa, Ryo, et al.
Publicado: (2019)

Albumin excretion rate among patients with diabetic retinopathy
por: Aman, Makbul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a6eclfhv8dkvauetjmi229a3de